Company Overview of Amedica Corporation

Amedica Corporation announced the 10,000(th) worldwide implantation of its Valeo Interbody Fusion Devices. The Valeo Interbody Fusion Device System, made of Amedica's proprietary Silicon Nitride ceramic technology, is used during surgical procedures to treat spinal disorders such as spondylolisthesis, scoliosis, severe disc degeneration, or spinal fractures.

Amedica Corporation announced that Karl Farnsworth has been named Chief Financial Officer (CFO) on February 21, 2013. Mr. Farnsworth brings more than 25 years of experience as a financial executive for growth-oriented, publicly traded companies in multiple industries. He most recently served as the Senior Vice President and Treasurer with Energy Solutions Inc. where he led working capital initiatives generating more than $30 million of sustainable cash. Prior to joining Amedica, Mr. Farnsworth served as CFO for Alcan Products Corporation, part of Alcan Inc., which was acquired by Rio Tinto Corporation in 2007. While at Alcan Inc. he spearheaded significant capital investments for the expansion of Alcan's global reach in manufacturing and market penetration into China and Mexico. Also during his tenure at Alcan, he directed a $200 million cash generation initiative throughout Europe and North America. Additionally, Mr. Farnsworth was appointed and served as a Director on the following corporate boards: Alcan Cable (Canada) Inc.; Stabiloy De (Mexico); EPA Holdings Ltd. (Hong Kong); APC Holding Corporation (USA); and, Alcan (Tianjin) Alloy Products Corporation (China).

Amedica Corporation announced that the company received a new patent for an artificial spinal disc implant based on its proprietary Silicon Nitride (Si(3) N(4)) ceramic material. Amedica's artificial spinal disc implant is unique in its design, material and construction. This is a distinct differentiation from existing metal-on-plastic or metal-on-metal designs. By leveraging Silicon Nitride, Amedica's artificial spine disc implant has the potential to provide patients with increased longevity of the implant due to lower wear, better osteointegration and reduced infection rates.